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ABSTRACT
The tumor suppressor p53 contributes to the cellu-
lar fate after genotoxic insults, mainly through the
regulation of target genes, thereby allowing e.g.
repair mechanisms resulting in cell survival or indu-
cing apoptosis. Unresolved so far is the issue,
which exact mechanisms lead to one or the other
cellular outcome. Here, we describe the interferon
regulatory factor-2-binding protein-2 (IRF2BP2) as
a new direct target gene of p53, influencing the
p53-mediated cellular decision. We show that upre-
gulation of IRF2BP2 after treatment with actinomy-
cin D (Act.D) is dependent on functional p53 in
different cell lines. This occurs in parallel with the
down-regulation of the interacting partner of
IRF2BP2, the interferon regulatory factor-2 (IRF2),
which is known to positively influence cell growth.
Analyzing the molecular functions of IRF2BP2, it
appears to be able to impede on the p53-mediated
transactivation of the p21- and the Bax-gene.
We show here that overexpressed IRF2BP2 has
an impact on the cellular stress response after
Act.D treatment and that it diminishes the induction
of apoptosis after doxorubicin treatment. Further-
more, the knockdown of IRF2BP2 leads to an upre-
gulation of p21 and faster induction of apoptosis
after doxorubicin as well as Act.D treatment.
INTRODUCTION
The loss of the tumor suppressor p53 appears to be a
crucial event in the development of cancer, since p53
plays an essential role in the cellular stress response
program. Germline mutations of p53 lead to a strong
cancer predisposition in mice and in humans (1).
Various forms of stress such as DNA damage, oncogene
activation, hypoxia, viral infection or nutrient deprivation
all induce the activation of p53 (2). Besides the regulation
of transcription-independent apoptotic pathways (3),
p53 mediates many of its key functions by transactivation
or transrepression of its target genes. It can recognize and
bind to speciﬁc DNA sequences, thereby recruiting general
and specialized transcriptional coregulators (4). Interest-
ingly, p53 can regulate target genes that promote growth
arrest and DNA repair, ultimately leading to cellular sur-
vival, as well as target genes that eventually trigger cell
death (5). Thus, one of the most important current
research questions is how the decision between the diﬀer-
ent p53-mediated response pathways is being made.
In general, the outcome of the p53-activation appears to
depend on the respective cell type, the nature of the stress
signal itself or the kind and extent of DNA damage, the
presence of survival factors in the cell and, if present,
inappropriate activity of oncogenes (6). The activity of
p53 itself seems to be inﬂuenced by the overall levels of
p53, post-translational modiﬁcations of p53, the presence
or absence of transcriptional cofactors and possible diﬀer-
ences in the p53-binding sequences of the potential target
genes (4,5).
For the induction of certain subsets of p53 target genes
distinct transcriptional factors are required, such as
CARM1, PRMT and JMY, that cooperate with the
CBP/p300 family of acetyl transferases to activate speciﬁc
p53 target promoters (7) as well as the long-range chro-
matin modiﬁer hCAS/CSE1L, which aﬀects diﬀerent
classes of p53 target genes (8).
For the induction of apoptosis, p53 alone appears not
to be suﬃcient, but it seems to require other factors bind-
ing to cis-elements in promoters of crucial genes (9) like
proteins of the ASPP-family (10) or the NF-kB transcrip-
tion factor that has been shown to inﬂuence the outcome
of p53-activity under certain cellular conditions (11). Also,
post-translational modiﬁcations appear to inﬂuence the
p53 response. Phosphorylation of serine 46, which was
reported to be crucial for p53-induced apoptosis, can be
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kinase cofactor and WIP1, a phosphatase (12,13). The fact
that both proteins are induced by p53 shows how tightly
the activity of p53 is regulated. While the binding of p53 to
its binding sites requires acetylation of its C-terminus
(14,15), the activation of certain apoptotic target genes,
like Bax and Puma, is associated with acetylation of
lysine 120 within the DNA-binding domain (16).
For the induction of growth arrest other cofactors are
responsible, e.g. proteins which mediate inhibition of cell-
cycle progression or those that impede on the induction of
apoptosis, like Miz (17), Hzf (18) or SLUG (19). Some of
these factors are target genes of p53 and although they do
not necessarily interact directly with p53, they can form
regulatory loops, delaying or inhibiting p53-mediated
apoptosis.
Within the interferon regulatory factor (IRF) family of
transcription factors that play important roles in antiviral
defense, immune response and cell-growth regulation,
IRF1 and IRF2 are generally described as a tumor sup-
pressor and an oncoprotein, respectively (20). IRF1 was
identiﬁed as the ﬁrst member of the IRF-family being
induced upon IFN-g and activating the transcription of
IFN-g responsive genes. IRF2 is also induced by IFN-g.
While IRF2 can bind to the same target gene sequences as
IRF1, it can act as an antagonist of the latter (21,22). In
addition to the repression of IRF1 induced target genes,
IRF2 has also been shown to promote cell proliferation
through the transcriptional activation of the histone H4
gene (23,24). Both IRFs are able to recruit the histone
acetyl transferases PCAF and CBP/p300 to target promo-
ters resulting in enhanced transcriptional activity (25).
Experiments in nude mice and expression pattern analysis
in several diﬀerent kinds of tumors support the hypothesis
that IRF1 can function as a tumor suppressor and IRF2
as an oncoprotein (26–29).
Interestingly, IRF1 can induce the growth arrest med-
iating p21 gene together with p53 (30). Although a binding
site for IRF1 was identiﬁed in the p21 promoter (31),
Dornan et al. (32) showed that this transactivation
depends on the interaction between IRF1 and p300. On
the other hand, knockdown of IRF2 or mutation of its
repressive C-terminus was shown to upregulate p21 tran-
scription (29,33), suggesting that this part of the protein,
at least in part, is responsible for its oncogenic potential.
Recently, a new nuclear factor, IRF2BP2, has been iden-
tiﬁed that interacts with the C-terminal repression domain
of IRF2 and that has the potential of an IRF2-dependent
transcriptional corepressor (34).
Here, we describe IRF2BP2 as a direct target gene of
p53. We show that p53 can bind in vivo and in vitro to a
p53 consensus-binding site upstream of the transcriptional
start site of the IRF2BP2 gene and that p53 can transac-
tivate its transcription. Functioning as a transcriptional
cofactor IRF2BP2 was able to inﬂuence the p53-mediated
transactivation of target genes as shown by luciferase
assays. Upon induction, IRF2BP2 promotes cell-cycle
arrest and seems to interfere with p53-mediated apoptosis
after chemotherapeutic treatment. When IRF2BP2 is
knocked down with small interfering RNA, stress-induced
p53-mediated apoptosis increases. We propose a function
of the new p53 target gene IRF2BP2 in a feedback-loop,
inﬂuencing the outcome of p53-activation in the direction
of growth arrest instead of apoptosis.
MATERIAL AND METHODS
Cellculture conditions
The human osteosarcoma cell line U2OS expressing wild-
type p53, the human osteosarcoma Saos-2 cell line, the
human embryonic kidney cell line HEK 293T, the synovial
sarcoma Syo-1, the lung adeno-carcinoma NCI-H460 and
the breast carcinoma MDA-MB231 cells were maintained
in Dulbecco modiﬁed Eagle medium supplemented with
10% fetal calf serum at 378C. The Tet-on inducible expres-
sion system (BD Biosciences) was used to generate a cell
line that conditionally express TAp73a in Saos-2 cells as
described previously (35). To generate p53 knockdown
cells the following oligos were cloned into a pSuper-
vector, which was transfected into U2OS cells:
pSuperp53-s 50-gatccccgactccagtggtaatctacttcaagagagta-
gattaccactggagtctttttggaaa-30 and pSuperp53-as 50-
agcttttccaaaaagactccagtggtaatctactctcttgaagtagattaccactg-
gagtcggg-30. Transfections were performed using the cal-
cium phosphate precipitation method (BES). Stable clones
were selected with 1mg/ml puromycin (Sigma).
The U2OS cells were treated for chromatin immunopre-
cipitation (ChIP) experiments and expression analysis, the
Syo-1, NCI-H460 and MDA-MB231 cells for expression
analysis with 5nM actinomycin D (Act.D) (Sigma) for
24h. For FACS analysis U2OS cells were treated either
with 2.5nM Act.D for 12h, or with 1nM doxorubicin
(Sigma) for 18 or 24h. IRF2BP2 knockdown cells were
treated for 24 or 48h either with 5nM Act.D or with
1nM, doxorubicin, respectively. The inducible Saos-2
cell line was ﬁrst induced with Doxycyclin (Sigma) for
24h and then additionally also treated with 5nM Act.D
for another 24h.
ChIP
The ChIP was basically done as described by Denissov
et al. (36). Brieﬂy, cells were crosslinked for 30min in
1% formaldehyde at room temperature. Crosslinking
was stopped by adding 125mM glycine. The cells were
washed three times, resuspended in lysis buﬀer and soni-
cated using a Bioruptor sonicator (Diagenode) for 15min
at high power, 30s ON, 30s OFF. Antibody incubation of
chromatin was performed overnight at 48C in incubation
buﬀer supplemented with 0.1% BSA with protein
A/G-Sepharose beads (Santa Cruz) and 1mg of antibody.
For U2OS cells, DO1 antibody (BD PharMingen) was
used to immunoprecipitate p53. For ChIP experiments
in the Saos-2 inducible cell line, BL906 (Abcam) was
used for p73a. Beads were washed sequentially with
four diﬀerent washbuﬀers at 48C. Precipitated chromatin
was eluted from the beads in 1% SDS and 0.1M
NaHCO3 at room temperature for 20min. Protein–DNA
crosslinks were reversed at 658C for 4h in the presence
of 0.2M NaCl, after which DNA was isolated by
phenol–chloroform extraction and ethanol precipitated
with 10mg of glycogen. Real-time (RT) PCR was
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MyIQ machine (Biorad). Primers used for RT PCR are
available upon request. Enrichment of the ChIP material
was calculated as recovery over an unspeciﬁc control
(myoglobin exon 2).
Electrophoretic mobility shift assay(EMSA)
TnT T7 Quick Coupled Transcription/Translation
System (Promega) was used for in vitro expression of
p53 starting with 500ng of pcDNA3-p53. 3ng of radio-
actively labeled oligonucleotides derived from the motifs
1–4 or the p53-binding motif of the p21-promoter were
incubated with IVT p53 and 1ml of p53 antibody
(pAb421; CalBiochem). 150ng of unlabeled wild-type or
mutant p21-oligonucleotide was used as competitor where
indicated.
RNA isolation andRT-PCR
Total RNA was extracted using the RNeasy Mini Kit
according to protocol (Qiagen). For cDNA synthesis, ret-
rotranscription was performed using 1mg of RNA with
oligo dT anchor primers, dNTPS, DTT, buﬀer and
Superscript Retrotranscriptase (Invitrogen). The cDNA
was analyzed by RT-PCR using a MyIQ machine
(Biorad). Primers used for RT-PCR are available upon
request. After quantitative PCR the obtained values
were normalized to GAPDH and induction of target
genes was calculated against the untreated control cells.
Constructionand transfections of plasmids
Full length cDNA of IRF2BP2A was subcloned from
pEF.IRF-2BP2A, a kind gift of S. Goodbourn, into
pcDNA3.1-FLAG using BamHI and XhoI.
The IRF2BP2–luciferase construct was made by PCR
ampliﬁcation of a 500bp region out of genomic DNA
from U2OS cells using the primers 50-ggagtcaccgtatactt-
tacttttca-30 and 50-ttttgaagcctctgacttcg-30 linked to attach-
ment sites of the Gateway Clonase system (Promega).
The binding site was subcloned into a promoter-contain-
ing pGL3-vector by using Gateway clonase. The muta-
tion of the central p53-binding motif was introduced
into the Gateway entry clone using the Quickchange Kit
(Stratagene).
U2OS and Saos cells were transiently transfected using
the calcium phosphate precipitation method (BES).
Transactivation assays
Saos and U2OS cells were transiently cotransfected with
500ng p53-responsive luciferase reporter constructs con-
taining either a sequence derived from the identiﬁed
p53-binding site upstream of the IRF2BP2 gene, a
p21- (a gift of Y. Tu) or a Bax-promoter (a gift of M.
Oren), 50ng pRL-TK Renilla reporter (Promega), 2mg
pcDNA3.1FLAG-IRF2BP2, 200ng pcDNA3.1FLAG-
p53 (a gift of K. Vousden) by calcium phosphate transfec-
tion. Empty pcDNA6 was used to equalize the amount of
transfected cDNA. Cells were lyzed and luciferase activity
was measured using the Dual-Luciferase Reporter Assay
System (Promega) according to protocol.
Cell-cycle analysis andquantification of apoptosis
Transfected and non-transfected cells treated as described
above were prepared for analysis as follows: cells were
grown in 10 mM BrdU for 1h, before ﬁxation in ethanol.
Cells were then stained with anti-BrdU-antibody (Dako)
and propidium iodide (Sigma) for 30min at room tem-
perature. DNA content was analyzed by ﬂow cytometry
(Becton Dickinson FACScan). The data was analyzed
using CellQuest Pro software.
RNAi-mediated knockdownof IRF2BP2
Stable knockdown of IRF2BP2 was mediated by lentiviral
infection of the following oligos targeting mRNA
sequences of IRF2BP2, which were cloned into the
pLKO-vector, containing a puromycin resistance gene
ﬂanked by LTRs used for genomic integration:
IRF2BP2 si1 50-caacggcttctccaagctaga-30; IRF2BP2 si2
50-gcagttgcaagaacagcaagg-30; IRF2BP2 si3 50-aactgcttga
attgtatatat-30. pLKO-Luciferase si 50-cgtacgcggaatac
ttcga-30 served as control. 1.8mg of the single pLKO–si
constructs, 1.8mg packaging vector R8.91 and 300ng
VSV-G were transfected into HEK 293T cells to produce
viral particles using Lipofectamin2000 (Invitrogen).
After 24h the supernatant was ﬁltrated and then used to
transduce target U2OS cells. The transduction was
repeated after 24h. On Day 3 the selection was started
with 1mg/ml puromycin (Sigma). Transient knockdown
of IRF2BP2 was achieved by using Dharmacon
ON-TARGETplus siRNAs, according to manufacturer’s
manual.
RESULTS
Identification ofIRF2BP2 asadirect target geneof p53
To obtain more insight into the molecular mechanisms
how the activation of p53 upon genotoxic stress can lead
to growth arrest and DNA repair or apoptosis, we have
previously performed a systematic analysis to identify new
binding sites for p53 in the human genome applying the
ChIP-on-chip technique on Act.D treated U2OS cells (35).
One of the interesting newly identiﬁed target genes was
IRF2BP2, an interacting partner of IRF2 (34). As
shown in Figure 1A, a p53-binding site was found 9kb
upstream of the promoter of the IRF2BP2 gene. Within
this binding site we could identify the p53 consensus bind-
ing motif, consisting of two halfsites with the sequence
RRRCWWGYYY (37). Scanning the surrounding
sequences of the IRF2BP2 gene for more potential p53
consensus binding motifs with the p53MH algorithm
(38), we found four diﬀerent motifs, each of them with a
score of more than 80% of the score of the ideal p53-
binding motif (Figure 1A and Table 1). These included a
motif (motif 4) upstream of the transcriptional start site,
corresponding to the site which was found by ChIP-on-
chip. Since we had found only this last motif bound by p53
in the ChIP-on-chip analysis we wanted to know if
the other predicted sites were really not bound in vivo
by endogenous p53. To this end, we performed targeted
ChIPs using an anti-p53 antibody to precipitate
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24h with 5nM Act.D and PCR-primers for all potential
binding sites. We veriﬁed that only the sequence for motif
4 is bound by p53 with a signiﬁcant enrichment
(Figure 1B). The binding strength of p53 towards the
motif 4 is comparable to its binding strength to the
known target gene Mdm2 (Figure 1B). In addition, we
found that p53 is also bound to motif 4 in untreated
U2OS cells, although to a much lesser extent
(Figure 1B). To obtain a complete analysis of the 5-kb
region upstream of the IRF2BP2 transcriptional start
site we designed primers every 500bp and tested
Figure 1. Identiﬁcation of a p53-binding site upstream of the IRF2BP2 gene. (A) ChIP-on-chip proﬁle from U2OS cells expressing p53. A region on
chromosome 1 including the IRF2BP2 gene is visualized using Signalmap (Nimblegen Systems Inc.). Cells were treated with 5nM Act.D for 24h
prior to chromatin isolation and ChIP with anti-p53 antibody. In the upper track the log 2 ratio of p53 ChIP material over input signal is shown.
Every bar represents one probe on the array. The lower track displays the location of the IRF2BP2 gene including a schematic representation of p53
motifs identiﬁed by the p53MH algorithm in the vicinity of the IRF2BP2 gene. Also shown are their locations relative to the IRF2BP2 gene. Motif 4
corresponds to the p53-binding site previously identiﬁed by ChIP-on-chip. (B) Binding of endogenous p53 in U2OS cells to the putative p53-binding
motifs. Cells were treated with 5nM Act.D for 24h or left untreated prior to chromatin isolation. Targeted ChIP was performed with primers for
Mdm2 and for sequences spanning the predicted motifs. Shown is the enrichment in fold over the negative control (myoglobin). Error bars represent
the standard deviation of three independent experiments. (C) Saos cells expressing p73a were induced with Doxycyclin for 24h prior to treatment
with 5nM Act.D for another 24h before chromatin was isolated. Targeted ChIP was performed using an anti-p73 antibody. Extent of binding of
p73a was determined by RT-PCR with primers used in (B). Error bars represent the SD of three independent experiments. (D) U2OS cells were
treated with 1nM doxorubicin for 24h, before chromatin was isolated. Targeted ChIP was done as in (B). (E) EMSA shows speciﬁc binding of p53
to the DNA-sequence containing motif 4. Labeled oligonucleotides spanning either the p53-binding site in the p21-promoter or DNA sequences of
the IRF2BP2 surrounding regions containing the motifs 1–4 were incubated with in vitro translated p53. In all lanes except lane 1 p53-antibody was
added to induce a supershift of the protein–DNA complexes. An unlabeled oligo containing the wild-type or a mutant p53-binding site of the p21-
promoter was used as a competitor to show speciﬁcity of binding. (F) The motif 4 containing p53-binding site can function as an enhancer. Saos cells
were transfected with a luciferase-construct containing either the wild-type or a mutant DNA sequence derived from motif 4, alone or together with
p53. Shown is the fold activation of the IRF2BP2 luciferase construct over the vector alone. Error bars represent the standard deviation of three
independent experiments.
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no p53 binding was observed (Supplementary Figure 1).
To analyze if IRF2BP2 is a common target gene of the p53
family, we compared the binding properties of p53 with
those of the closely related protein p73a. For this purpose,
we used a Saos osteosarcoma cell line stably expressing
p73a under the control of an inducible promoter (35).
After the induced expression of p73a, the cells were treated
with 5nM Act.D for 24h prior to chromatin isolation.
DNA bound by p73a was precipitated using anti-p73 anti-
body and RT-PCR was performed with the indicated pri-
mers. We veriﬁed that the p53-binding site upstream of the
IRF2BP2 gene is bound by p73a in this Saos cell line upon
Act.D treatment to the same extent as the known binding
site of Mdm2 (Figure 1C). To test whether binding of
p53 to the binding site upstream of IRF2BP2 is restricted
to Act.D treatment or a more general response, we also
performed targeted ChIP from U2OS cells treated for
24h with 1nM doxorubicin (Figure 1D). We found that
the IRF2BP2-binding site was also strongly bound by p53
upon doxorubicin treatment. Next we tested if one or more
of the identiﬁed motifs were directly bound by p53.
Therefore we performed EMSA on radioactive labeled
nucleotides spanning each of the predicted p53-binding
sites, motifs 1–4, (Figure 1E). The p21-binding motif was
used as a positive control. After incubation of the diﬀerent
nucleotides together with p53 and an anti-p53 antibody, a
supershift could be observed after incubation of p53 with
motif 4, but not with the motifs 1–3. To show the speciﬁcity
of the binding an excess of unlabeled p21-binding motif
was added, either the wild-type or a mutant sequence (as
indicated). To analyze whether the identiﬁed p53-binding
site upstream of the IRF2BP2 gene also has a potential
transactivating property, we cloned a 500-bp fragment
containing the sequence around motif 4 into a luciferase
vector. This vector contains a basic promoter and therefore
can be used for testing potential enhancer activity. Upon
cotransfection of this pGL3-IRF2BP2-luc vector together
with p53 into Saos cells, luciferase activity increased 3–4-
fold, compared to the luciferase vector transfected alone
(Figure 1F). A mutation in the central binding motif for
p53 from CATG to TATA abolished the transactivation,
thus proving a speciﬁc and functional p53-binding site.
Thus, we veriﬁed an in vivo binding site for p53
upstream of the IRF2BP2 gene, which had originally
been identiﬁed by our ChIP-on-chip approach. Although
more binding motifs were predicted by the p53MH algo-
rithm, we found that they were not bound by p53 in
U2OS cells after Act.D as well as doxorubicin treatment.
Furthermore, this newly identiﬁed p53-binding site could
also be bound by p73a. In addition, we found that this
sequence is also bound in vitro by p53 and it can poten-
tially function as a p53-dependent enhancer sequence as
shown by luciferase assays.
Figure 1. Continued.
Table 1. Putative p53-binding motifs close to the IRF2BP2 gene
Sequence Location relative
to IRF2BP2-gene
Identity
score
(%)
Motif 1 TGGCATGCCC <6bp> CAACATGCCC 0.4kb downstream 96.57
Motif 2 GGACTAGCCT <8bp> CACCAAGTGC 1.4kb upstream 83.60
Motif 3 AAACATGCCT <9bp> ACACATGTGA 7.3kb upstream 81.49
Motif 4 AAACATGTCA <0bp> GGACATGCCT 9.0kb upstream 95.27
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Next we examined whether p53 binding also leads to a
change in IRF2BP2 expression. To test to which extent
the regulation of IRF2BP2 expression is dependent on
p53, we compared its expression change in wild-type
U2OS cells with the expression change in U2OS p53
knockdown cells upon stress treatment. Although the
knockdown of p53 is not complete in these cells, the
p53 protein levels are markedly decreased (Figure 2A).
The respective cells were either treated with 5nM Act.D
for 24h or left untreated. In treated cells the expression
of IRF2BP2 increases 2-fold compared to untreated
cells, which is comparable to the p53-induced activation
of the known p53 target gene Bax under the same physio-
logical conditions (Figure 2B). However, the cells contain-
ing the p53 knockdown do not show increased mRNA
levels of IRF2BP2 nor Bax upon treatment, thus suggest-
ing a p53-dependent induction of IRF2BP2. A similar
induction of IRF2BP2 mRNA could be observed after
treatment with Etoposide (data not shown). To further
validate that the observed induction of IRF2BP2
indeed is mediated directly through p53, we studied the
kinetics of its expressional change (Figure 2C). The level
of IRF2BP2 mRNA increases 6h after stabilization of
p53 and reaches its highest level after 24h of treatment,
showing kinetics which could reﬂect a direct response to
p53 and which are comparable to the kinetics of Bax
mRNA induction upon the same treatment (data not
shown). In our previous study (35) we also found a bind-
ing site for p53 close to the IRF2 gene. Because IRF2 is a
protein directly interacting with IRF2BP2 (34), we were
interested to analyze whether the expression of IRF2 also
changed over time upon treatment with Act.D. We
observed a decrease of IRF2 expression to 50% during
the ﬁrst 12h of treatment. However, after 24h the levels
of IRF2 mRNA were restored to the same relative mRNA
levels as of unstressed cells (Figure 2C). Since p73a could
bind to the upstream sequence of IRF2BP2 as well, we
wanted to know whether p73a was also able to induce
the expression of the IRF2BP2 gene. Therefore we ana-
lyzed RNA isolated from the p73a-expressing Saos cells,
which had been treated with Act.D. Although p73a can
bind the same site as p53, induction of p73a does not
lead to an elevated expression of IRF2BP2 mRNA
(Figure 2D), while known target genes like GADD45 or
Mdm2 are upregulated after p73a-induction (data not
shown).
As expression levels of a certain mRNA species may
vary between several cell types we analyzed more cell
lines for their expression of IRF2BP2 upon stress treat-
ment: synovial sarcoma cell line Syo-1 and NCI-H460
cells derived from a lung adeno-carcinoma, both con-
taining wild-type p53 and a breast carcinoma cell line,
MDA-MB231 without functional p53. The expression of
IRF2BP2 was analyzed under the same conditions as
used before (Figure 2E). The induction of IRF2BP2
mRNA in the Syo-1 and NCI-H460 cell lines was com-
parable to the one observed in U2OS cells. Strikingly, in
MDA-MB231 cells the level of IRF2BP2 mRNA did not
increase upon Act.D treatment and those cells do not
contain functional p53. Thus, it appears that the expres-
sion change of IRF2BP2 mRNA upon Act.D treatment
seems to depend on the activation of functional p53 in
several diﬀerent tumor cell lines.
Figure 2. Upregulation of IRF2BP2 after p53 induction. (A)
Induction of p53 in U2OS wild-type or p53 knockdown cells. Cells
were treated with 5nM Act.D for 24h, before whole cell extracts
were prepared and protein levels of p53 and tubulin as loading control
were determined. (B) Expression changes in U2OS wild-type and
p53 knockdown cells after treatment with 5nM Act.D for 24h,
compared to untreated cells. Whole RNA was extracted and quantita-
tive RT-PCR was performed, with primers for IRF2BP2 and Bax.
Upregulation is shown after normalization against GAPDH and
calculated over the untreated control. Error bars represent the SD of
three independent experiments. (C) Kinetics of expression changes
of IRF2BP2 and IRF2 upon Act.D treatment. U2OS cells were treated
for the indicated time points with 5nM Act.D before whole RNA
was isolated, followed by quantitative RT-PCR for IRF2BP2
and IRF2 expression. Error bars result from two independent
experiments. (D) Induction of target genes by p73a in Saos t.o.
cells induced for 24h and treated with 5nM Act.D for another 24h
prior to RNA isolation. Error bars represent the SD of three
independent experiments. (E) Human cell lines containing wild-type
p53 (Syo1, NCI-H460) or no functional p53 (MDA-MB231) were trea-
ted with 5nM Act.D for 24h. Changes in the levels of IRF2BP2
mRNA are shown after normalization to GAPDH and calculated
against untreated controls. Error bars result from two independent
experiments.
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Recently the IRF2BP2 related protein IRF2BP1 was iden-
tiﬁed as an ubiquitin ligase (39). Since IRF2BP2 shares the
C3H4 RING ﬁnger with IRF2BP1, which mediates the
transfer of ubiquitin molecules and since p53 is regulated
through ubiquitination (40), we decided to test whether
IRF2BP2 could inﬂuence the protein stability of p53 by
transfecting U2OS cells with p53 and increasing amounts
of IRF2BP2 or vice versa (Figure 3A). We could not
detect that IRF2BP2 changes the levels of cotransfected
p53 nor that p53 could change the protein levels of trans-
fected IRF2BP2. To unravel the functional consequence
of the IRF2BP2 upregulation, we investigated whether
IRF2BP2 could have an inﬂuence on the transactivation
of p53-dependent promoters, which would be comparable
to its described function as a transcriptional corepressor of
IRF2 (34). Therefore we transfected U2OS or Saos cells
with p53 and IRF2BP2 expression constructs together
with diﬀerent luciferase reporter constructs containing
known target gene sequences. Neither p53 nor IRF2BP2
have an eﬀect on the basic pGL3–luciferase construct
(pGL3–luc), which does not contain a p53-response
element (data not shown). The cotransfection of p53
together with a Bax–luciferase construct (Bax–luc) leads
to a 150 times higher luciferase activity of the Bax–luc
construct than the transfection of the reporter construct
alone (Figure 3B). Very interestingly, the IRF2BP2
overexpression alone has no eﬀect on the transactivation
of the Bax–luc construct, but upon cotransfection of
p53 and IRF2BP2, we could observe an inhibition of the
p53-mediated activity of Bax–luc up to 75% (Figure 3B).
To test whether this eﬀect was dose-dependent we
increased the amounts of transfected p53 from 200ng to
2000ng, while holding the IRF2BP2 levels equal. At the
highest amount of cotransfected p53, the luciferase level is
restored to the level reached with p53 alone (Figure 3C).
To test whether the inhibition mediated by IRF2BP2
was speciﬁc for the Bax–luc construct, we also tested a
p21–luciferase construct (p21–luc) in cotransfections
with p53 and IRF2BP2. Also with the p21–luc construct
we observed that the p53-mediated transactivation was
impeded by the cotransfection of IRF2BP2 (Figure 3D).
We also tested a p21–luc construct in which the distal,
high-aﬃnity binding site of p53 in the p21 promoter
was deleted, p21–luc delta p53 (41). As expected, the
p53-transactivation of this deletion construct was reduced
to less than 50% of the activity of the wild-type construct,
although a certain luciferase activity was still seen prob-
ably due to the low-aﬃnity binding site of p53 present in
the p21-promoter (Figure 3E). Interestingly, IRF2BP2
coexpression was able to reduce also the p53-mediated
transactivation of this deletion luciferase construct.
Thus, the eﬀect of IRF2BP2 on the transactivation activ-
ity of p53 does not seem to be dependent exclusively on
the high-aﬃnity binding site of the p21 promoter. To
analyze the eﬀect of IRF2BP2 on the expression of endo-
genous genes regulated by p53, we transfected cells with
IRF2BP2 and subsequently treated them with Act.D
before changes in the mRNA-levels were analyzed.
We found a slight, but signiﬁcant downregulation of
p21–mRNA in IRF2BP2 transfected cells compared to
the control cells (Figure 3F). Thus, IRF2BP2 seems to
have a repressing eﬀect on the transactivation function
of p53 towards its target genes and this repression can
be overcome by increasing the protein levels of p53, with-
out changing the protein stability of p53.
Overexpression ofIRF2BP2 influencesthe induction of
apoptosis after genotoxic stress
Since IRF2BP2 was described as a binding partner of
IRF2, which is involved in the positive regulation of the
cell cycle, we wanted to examine a possible role of
IRF2BP2 during cell cycle regulation, especially upon che-
motherapeutic treatment, since we had found IRF2BP2 to
be upregulated during the p53 response to Act.D. Two
major response pathways mediated by p53 after genotoxic
insults are growth arrest and apoptosis. To stimulate
these responses we treated U2OS cells transfected with
IRF2BP2 either with 2.5nM Act.D or 1nM doxorubicin,
for 12–24h to induce growth arrest or apoptosis, respec-
tively. The eﬃciency of tranfection was monitored by
GFP, to ensure that at least 60% of the cells were trans-
fected. To discriminate between the diﬀerent phases of the
cell-cycle BrdU staining was performed. In untreated
IRF2BP2 transfected cells, a slight but signiﬁcant increase
in the S-phase population (48% in IRF2BP2 transfected
cells versus 41% in the control cells) and a decrease of cells
in the population in G2-phase (26% in IRF2BP2 trans-
fected cells versus 31% in the control cells) can be
observed compared to the control cells transfected with
empty vector DNA only (Figure 4A). Upon Act.D treat-
ment we observed a slight increase of S-phase in the con-
trol cells (from 41% to 47%), whereas IRF2BP2
transfected cells show a statistical signiﬁcant decrease in
S-phase (from 47% to 39%) (Figure 4B). Furthermore,
the G1-population of the control cells was reduced from
23% to 16%, which was not seen in the IRF2BP2 trans-
fected cells. On the other hand we observed an increase in
the G2-phase of Act.D-treated, IRF2BP2 transfected cells
(from 26% to 35%). The treatment of cells with doxoru-
bicin for 18h or 24h induces several changes in the cell-
cycle distribution, without signiﬁcant diﬀerences between
the IRF2BP2- and the control transfected cells (Figure 4C
and D). However, doxorubicin leads after 18h to a strong
increase in the G2-phase in both transfected cell popula-
tions, up to 50%, whereas the populations of G1- and
S-phase cells decrease. This is reversed after 24h of treat-
ment with doxorubicin, the amounts of cells in each phase
of the cell cycle vary now between 20–30%.
Finally, we examined the induction of apoptosis after
treatment in cells transfected with IRF2BP2 compared to
cells transfected with empty vector only. After transfection
and treatment, PI-staining was performed and the Sub-G1
population was determined (Figure 4E). Upon treatment
with Act.D the levels of apoptosis do not increase com-
pared to untreated cells, although the Sub-G1 population
in the IRF2BP2 transfected cells is signiﬁcantly smaller
compared to the control transfection (4% in IRF2BP2
transfection; 7% in the control cells). The treatment
with doxorubicin induces apoptosis already after 18h,
328 Nucleic Acids Research, 2009, Vol. 37, No. 2Figure 3. IRF2BP2 is able to inﬂuence the transactivation of p53-responsive promoters. (A) Neither p53 nor IRF2BP2 have an inﬂuence on each
other’s protein stability. U2OS cells were transfected either with p53 and increasing amounts IRF2BP2 or vice versa and 24h later the indicated
proteins were detected by western Blot. GFP staining was used to ensure equal transfection eﬃciency. (B) IRF2BP2 can impede on the p53-
transactivation of Bax-luc. A luciferase reporter construct containing the Bax-promoter was transfected into U2OS cells together with p53,
IRF2BP2 or an empty vector, as indicated. Luciferase activity was normalized to Renilla. Error bars represent the SD of three independent
experiments. (C) Higher p53 levels can reverse the eﬀect of IRF2BP2 on Bax–luc. Increasing amounts of p53-plasmid were transfected, ranging
from 200ng to 2000ng, together with Bax-luc and 2000ng of IRF2BP2 where indicated. (D) IRF2BP2 can impede on the p53-transactivation of
p21–luc. Saos cells were transfected with a luciferase-construct containing the p21-promoter together with p53, IRF2BP2 or empty vector where
indicated. (E) The high-aﬃnity site of p53 is not required for IRF2BP2 function. Saos cells were transfected with p53, IRF2BP2 or empty vector
where indicated together with a luciferase construct containing the p21-promoter lacking the high-aﬃnity binding site for p53. (F) Overexpressed
IRF2BP2 can inﬂuence the expression of p21. U2OS cells were either tranfected with empty vector or IRF2BP2. Cells were treated with 5nM Act.D
for 24h before RNA was isolated and mRNA of p21 was analyzed by qPCR. Error bars represent the SD of three independent experiments. The
asterisk indicates statistical signiﬁcance shown by Student’s t-test (P<0.05) compared to control transfection.
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in the cells transfected with empty vector to a total of 14%
after 24h of treatment. In IRF2BP2 transfected cells the
population of apoptotic cells is signiﬁcantly smaller, even
after 24h less than 9% of the cells undergo programmed
cell death.
From this we concluded, that IRF2BP2 can induce
some changes in the cell cycle of living cells, mainly it
changes the S-phase population, which increases in
untreated and decreases in Act.D treated cells, compared
to control transfections. Interestingly, IRF2BP2 appears
to impede or diminish the induction of cell death after
apoptotic stimulation.
More rapid apoptosis after chemotherapeutic treatment in
IRF2BP2 knockdowncells
To investigate the function of IRF2BP2 during cell cycle
under more physiological conditions, we downregulated
the endogenous levels of IRF2BP2 by introducing
Figure 4. Cell-cycle changes after overexpression of IRF2BP2. Cell-cycle analysis of U2OS cells transfected either with an empty vector or with an
IRF2BP2-expression construct. Transfection eﬃciency was monitored by GFP and BrdU-staining was performed for analysis. (A) The transfected
cells were left untreated prior to harvest. (B) After transfection the cells were treated with 2.5nM Act.D for 12h prior to cell-cycle analysis.
(C) Treatment of the transfected cells with 1nM of doxorubicin for 18h. (D) Treatment of the transfected cells with 1nM of doxorubicin
for 24h. (E) Determination of levels of apoptosis after transfection of cells with IRF2BP2 or empty vector. Sub-G1 population was measured
after treatment of cells by propidium iodide staining. All SD result from three biological replicas, each performed in duplicate. Statistical signiﬁcance
was determined by Student’s t-test (
 P<0.05;
  P<0.01;
   P<0.001).
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mRNA. We monitored the eﬃciency of the knockdown
by analyzing the transcript levels of IRF2BP2 in U2OS
cells 24h after treatment with 5nM Act.D and observed a
signiﬁcant reduction of IRF2BP2 expression, especially
after Act.D treatment compared to the cells transfected
with non-targeting siRNAs (Figure 5A). Furthermore,
we analyzed the knockdown eﬃciency by western blotting.
Due to the lack of a speciﬁc IRF2BP2 antibody we trans-
fected FLAG-IRF2BP2 into the knockdown and the con-
trol cells. Figure 5A shows that the knockdown of the
transfected protein is under these circumstances almost
complete. Equal levels of transfection were monitored by
GFP cotransfection.
First, we analyzed whether the p21 and Mdm2 expres-
sion levels were inﬂuenced by the knockdown of
IRF2BP2. We observed a small, but reproducible and sig-
niﬁcant increase of p21 expression levels upon Act.D
treatment in the IRF2BP2 knockdown cells in comparison
to the control cells. The Mdm2 expression level, on the
other hand, stays the same in IRF2BP2 knockdown as
well as the control cells (Figure 5B). To test the possibility
Figure 5. Knockdown of IRF2BP2 renders cells sensitive to chemotherapeutic stress. (A) Knockdown of IRF2BP2 in U2OS cells using lentiviral
vectors or ON-TARGETplus oligo siRNAs. Eﬃciency of the knockdown was monitored by analyzing the transcript-levels of IRF2BP2 relative to
GAPDH and by transient retransfection of 500ng FLAG-IRF2BP2 followed by western blotting with anti-FLAG antibody. GFP-staining was used
to monitor transfection eﬃciency. SD was derived from three biological replicas. Asterisk indicates statistical signiﬁcance shown by Student’s t-test
(P<0.05) compared to non-targeting siRNA. (B) Expression analysis showing the induction of p21 and Mdm2 mRNA in the control and the
IRF2BP2 knockdown cells after treatment with 5nM Act.D for 24h. SD was derived from three independent experiments. Asterisk indicates
statistical signiﬁcance shown by Student’s t-test (P<0.05) compared to non-targeting siRNA. Western blot showing the levels of p53 and p21 in
the IRF2BP2 knockdown and the control siRNA cells. TBP was used as a loading control. Whole cell extracts of the IRF2BP2 knockdown and the
control cells were prepared after treatment with either Act.D or doxorubicin and 15mg of protein from each sample were used for western blot and
stained against the indicated proteins. (C) Activation of Caspase 3 after chemotherapeutic treatment. IRF2BP2 knockdown or control cells were
treated for the indicated times with 5nM Act.D (left panel) or with 1nM doxorubicin (right panel) before Caspase 3 levels were analyzed. Tubulin
was used as loading control. (D) Quantiﬁcation of apoptosis determined by FACS analysis of the control (left) and the IRF2BP2 knockdown (right)
cells. Cells were treated for the indicated times with 5nM Act.D prior to harvest and propidium iodide staining for FACS. Apoptotic Sub-G1
population is shown as percentage of all cells. SD was derived from three independent experiments. Asterisks indicate statistical signiﬁcance shown
by Student’s t-test (P<0.05) compared to the non-targeting siRNA. (E) Quantiﬁcation of apoptosis after treatment with 1nM doxorubicin. After the
indicated time points IRF2BP2 knockdown and control cells were harvested and propidium iodide staining was performed. Apoptotic Sub-G1
population is shown as percentage of all cells. SD was derived from three independent experiments. Asterisks indicate statistical signiﬁcance shown
by Student’s t-test (P<0.05) compared to the non-targeting siRNA.
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feedback-loop comparable to the one of Mdm2, we ana-
lyzed whether the protein levels of p53 and p21 were
aﬀected in the IRF2BP2 knockdown cells (Figure 5B).
In untreated cells very low levels of p53 and p21 are pre-
sent, without any diﬀerence between the IRF2BP2 knock-
down and the control cells. After treatment with Act.D,
p53 and also p21 accumulates. While p53 levels seem to be
very similar in the knockdown and the control cells, we
observed slightly higher p21 protein levels in the IRF2BP2
knockdown cells upon Act.D treatment. Thus, IRF2BP2
knockdown most likely does not change the stability of
p53 or Mdm2, but slightly increases the levels of p21
mRNA and protein.
Since overexpressed IRF2BP2 had an inﬂuence on the
cell cycle, we also examined the eﬀect of IRF2BP2 knock-
down followed by stress treatment. Using BrdU staining
we wanted to detect diﬀerences in the cell cycle between
control and IRFBP2 knockdown cells, but we could not
observe any signiﬁcant changes in the distribution of cells
in G1-/S- or G2-phase (data not shown). Very interest-
ingly, we found again signiﬁcant diﬀerences in the induc-
tion of apoptosis (Figure 5C). Control and IRF2BP2
knockdown cells were treated either with 5nM Act.D or
with 1nM doxorubicin for the indicated time points,
before the activation of Caspase 3 was analyzed. After
both treatments the cells containing the IRF2BP2 knock-
down show higher levels of active Caspase 3 already after
24h. To quantify this eﬀect we measured the Sub-G1
population by FACS after propidium iodide staining.
Under unstressed conditions the IRF2BP2 knockdown
and the control siRNA transfection show similar levels
of spontaneous apoptosis (Figure 5D). After the induction
of a stress response, mediated through 5nM Act.D, the
knockdown of IRF2BP2 leads to a slight accumulation of
apoptotic cells after 24h, this population increases after
48h in total almost 4-fold compared to the untreated cells.
The respective increase of the apoptotic population in the
control cells is signiﬁcantly smaller upon Act.D treatment.
When treated with 1nM doxorubicin for 24h IRF2BP2
knockdown cells already display twice the amount of
apoptotic cells compared to the control (Figure 5E).
After 48h of treatment with doxorubicin the control and
the knockdown cells accumulate high levels of apoptotic
cells, with the amount of apoptotic cells being 10% higher
in the IRF2BP2 knockdown cells. Our interesting obser-
vation that the IRF2BP2 knockdown cells are more sen-
sitive to chemotherapeutic treatment and undergo
apoptosis more rapidly hints at a role of endogenous
IRF2BP2 in the inhibition of cell death.
DISCUSSION
In this study we identiﬁed the transcriptional coregulator
IRF2BP2 as a new, direct target gene of p53. The binding
site we found was bound in vivo and in vitro by p53 and it
had transactivating potential. We showed that IRF2BP2
participates in the genotoxic response mediated by p53,
inﬂuencing the stress response pathways of the cells. We
observed an upregulation of IRF2BP2 mRNA after treat-
ment with Act.D in diﬀerent cell systems containing func-
tional p53, but not in cells without functional p53.
Analyzing the function of IRF2BP2 after its overexpres-
sion as well as its knockdown, we found that it inﬂuences
the cellular response after genotoxic insults. Its overex-
pression without stress treatment seems to slightly increase
the population of cells in S-phase. This might be due to
an IRF2BP2-mediated stabilization of IRF2 containing
Figure 5. Continued.
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gene (23). This gene is regulated during cell cycle with a
peak in transcription during early S-phase (23,24). When
U2OS cells are exposed to doxorubicin, the overexpres-
sion of IRF2BP2 seems to delay the induction of apopto-
sis. On the other hand cells overexpressing IRF2BP2
display an reduced S-phase population after low doses
of Act.D. In line with this, the knockdown of IRF2BP2
leads to increasing amounts of apoptotic cells after dox-
orubicin treatment and also after treatment with Act.D,
which normally rather causes growth arrest. This points
towards an important function of IRF2BP2 in the deci-
sion between cellular survival and programmed cell death.
From this data the question rises for which purpose p53
induces IRF2BP2, a factor that appears to delay or dimin-
ish apoptosis. Here we suggest a role for IRF2BP2 in
maintaining a cell growth arrest state, which might allow
the cells to repair damaged DNA.
After the identiﬁcation of IRF2BP2 as an interaction
partner of IRF2, it had been speculated that they act
together to inhibit the tumor suppressor function of
IRF1 by impeding on the IRF1 mediated induction of
p21 (31). Our IRF2PB2 knockdown data seem to support
this model: We observe a slight upregulation of p21
expression and more apoptosis after chemotherapeutic
treatments in IRF2BP2 knockdown cells. These observa-
tions are very similar to the eﬀect of the IRF2 knockdown
cells in which the p21 expression is also upregulated and
more spontaneous apoptosis is found (29). Thus, while
physiological levels of IRF2 can upregulate the anti-
apoptotic Bcl-2 (29), the knockdowns of IRF2 as well as
the knockdown of IRF2BP2 seem to have a pro-apoptotic
eﬀect.
According to a current model of the p53 response, low
doses of cellular stress that occur more frequently do not
lead to apoptosis although they activate p53. Higher doses
of stress can damage the cell irreversibly, leading to apop-
totic cell death (6). Both pathways seem to be inﬂuenced
by groups of cofactors, driving the cellular outcome
towards one or the other decision depending on the kind
and extent of genotoxic stress. The induction of growth
arrest requires other cofactors than the apoptotic path-
way, and some of them are transcriptional targets of
p53, thereby forming feedback loops and regulating the
outcome of p53-activation. An important factor is the
zinc-ﬁnger containing protein Hzf, which is found in a
transcriptional complex with p53 and can target this com-
plex preferentially to promoters of genes involved in
growth arrest, but not in apoptosis (18). Since the induc-
tion of growth arrest should allow DNA-repair and
eventually cell survival, it also requires a temporary inhi-
bition of apoptotic induction. Thus, notably, other target
genes of p53 are involved in the inhibition of apoptosis,
like the transcriptional repressor SLUG that can repress
the expression of puma, a BH3-only protein, which is a
key mediator of apoptosis in hematopoietic progenitor
cells (19).
We found here that IRF2BP2 might function in a com-
parable way, since it was able to inhibit p53-mediated
p21- and Bax–luc transactivation, but this inhibition of
Bax–luc transactivation could be overcome if higher
levels of p53 were present. A similar mechanism has also
been described for Hzf, where after prolonged p53-activa-
tion, Hzf is degraded and p53-activity is rendered towards
pro-apoptotic genes (18). This could happen for example
upon higher doses of stress leading to an accumulation of
p53, thereby passing a certain apoptotic threshold fol-
lowed by the induction of programmed cell death (5).
Since we could not detect a direct interaction
between p53 and IRF2BP2 (data not shown) it is possible
that the regulation of p53 target genes by IRF2BP2 is
mediated through IRF2 to which the transcriptional
factor IRF2BP2 binds. We observed a downregulation
of IRF2 around 2-fold after 6h of Act.D treatment.
IRF2 is an antagonist of the growth suppressor IRF1,
which is involved in the induction of p21 (30) and the
ratio of IRF2:IRF1 is believed to be an important deter-
minant in the regulation of cell growth (42). Besides the
activation of H4-transcription (23), IRF2 is able to stimu-
late the transcription of diﬀerent regulatory subunits of
checkpoint kinases, like cyclin D1 or cyclin B1 and it
was also shown to upregulate the anti-apoptotic Bcl-2
protein, displaying features of a proto-oncogene (29,43).
Furthermore, high levels of IRF2 keep IRF1 from enter-
ing the nucleus (29). The concerted regulation of IRF2
and IRF2BP2 might display a mode of dual action of
p53 through the upregulation of IRF2BP2 on the one
hand and the downregulation of IRF2 on the other
hand. Thereby the balance between growth stimulating
and inhibiting activities of the IRF1:IRF2 ratio could be
changed (26) and growth arrest pathways could be posi-
tively inﬂuenced.
It has been reported, that both IRF1 and IRF2 directly
activate or repress target genes. The binding element both
proteins compete for is known as PRDI/CCE (23,44) or
ISRE (34) and this element has been implicated to have
activating as well as repressing functions. We found sev-
eral copies of it in the here used luciferase constructs by
Match-analysis using the Transfac-database (Transfac
professional 11.1). Furthermore, Coccia et al. veriﬁed
one out of ﬁve putative ISRE-elements 1.2kb upstream
of the p21 transcriptional start site as a true binding site
for IRF1/2 (31). Surprisingly the motif in the p21 promo-
ter found by Coccia et al. (31) seems to be dispensable for
the IRF1 mediated enhancement of p21 activation by p53,
since this enhancement was shown to be the result of an
interaction of IRF1 with p300 leading to increased p53
acetylation and higher transcriptional activity towards
p21 (32). Interestingly, the domain of p300 interacting
with IRF1 maps in the same region as the interacting
domains of JMY and p300, maybe leading to an mutual
exclusive activation of either pro-apoptotic or pro-growth
arrest target genes (32,44). A further possible mechanism
of repression of p53 target genes might involve the PU.1
protein. This transcriptional cofactor reduces the tran-
scriptional activity of p53 and it directly interacts with
IRF2 (45,46). Besides a high degree of homology in
their DNA-binding domain, the C-terminus of IRF2 is
unique compared to IRF1 and it can recruit IRF2BP2
to DNA, thereby mediating transcriptional repression
towards artiﬁcial promoter constructs (34). Nonetheless,
the exact circumstances leading to activation or repression
Nucleic Acids Research,2009, Vol. 37,No. 2 333through IRF1 or IRF2 are still unclear. Thus, the
IRF2BP2 induction by p53 could be the direct link
between the p53 pathways upon cellular stress and the
for the cell cycle progression so important balance
between the IRF1 and IRF2 activities.
Thus, the here observed induction of IRF2BP2 expres-
sion after p53-activation appears to play an interesting
role to inﬂuence the cellular stress response. As a possible
mechanism we propose that IRF2BP2 modulates p53
transcriptional activity, by decreasing the p53-mediated
p21- and Bax-transactivation until the p53 levels increase
and the IRF2BP2-mediated repression is reversed. Our
ﬁndings suggests that IRF2BP2 might be part of a new
feedback-loop for the cells after p53 activation, increasing
the threshold for induction of apoptosis, but also inhibit-
ing the progression of cell cycle, possibly to allow repair of
damaged DNA.
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